07:00 , Aug 15, 2016 |  BioCentury  |  Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

STI-001: Phase III data

A double-blind, Chinese Phase III trial in 501 patients with EGFR-expressing metastatic colorectal carcinoma showed that STI-001 plus irinotecan led to an ORR of 32.9%, PFS of 5.6 months and OS of 14.1 months vs....
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

STI-002: Phase III data

A Chinese Phase III trial in 330 RA patients showed that 3 mg/kg STI-002 plus methotrexate led to an ACR20 response rate of 77%. ACR50 and ACR70 response rates were 50% and 20%, respectively....
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Mabtech, Sorrento deal

Mabtech granted Sorrento exclusive rights to develop and commercialize four undisclosed biosimilar mAbs in North America, Europe and Japan. The antibodies have completed Phase III testing. Sorrento said one mAb is for cancer, one is...
07:00 , Aug 22, 2005 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Oxford Immunotec Ltd. Oxford, U.K. Technology: T SPOT technology to assess T cell response Disease focus: Infectious Clinical status: Market Founded: 2002 by Ajit Lalvani and Peter Wrighton-Smith University collaborators: Oxford University Corporate partners: NA Employees: 24 Funds raised: £10 million ($18.6 million) Investors:...
08:00 , Mar 18, 2002 |  BC Week In Review  |  Company News

Seattle Genetics, Mabtech AB deal

Mabtech granted SGEN an exclusive license to certain monoclonal antibodies that target cell surface molecules on a variety of cancer cells. SGEN said it will evaluate the antibodies as therapeutic agents alone and with its...
08:00 , Mar 14, 2002 |  BC Extra  |  Company News

Seattle Genetics, Mabtech cancer MAb deal

Mabtech (Nacka, Sweden) granted SGEN an exclusive license to certain monoclonal antibodies that target cell surface molecules on a variety of cancer cells. SGEN said it will evaluate the antibodies as therapeutic agents alone and...